Research Analysts Set Expectations for BDTX FY2026 Earnings

Key Points

• HC Wainwright predicts Black Diamond Therapeutics will have an earnings per share of ($1.04) for FY2026, maintaining a "Buy" rating with a price target of $10.00.
• Black Diamond has received mixed ratings from analysts, with Wall Street Zen downgrading it to a "hold" while Raymond James upgraded it to "outperform" with a $11.00 target price.
• The stock has a market capitalization of $152.26 million and has traded between $1.20 and $6.75 over the past year, with institutional investors holding 95.47% of shares.

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) - Analysts at HC Wainwright issued their FY2026 earnings per share estimates for shares of Black Diamond Therapeutics in a research report issued to clients and investors on Monday, August 11th. HC Wainwright analyst R. Burns forecasts that the company will post earnings per share of ($1.04) for the year. HC Wainwright has a "Buy" rating and a $10.00 price target on the stock. The consensus estimate for Black Diamond Therapeutics' current full-year earnings is ($1.30) per share.

Black Diamond Therapeutics (NASDAQ:BDTX - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.06.

Other equities analysts have also recently issued research reports about the stock. Raymond James Financial raised shares of Black Diamond Therapeutics to an "outperform" rating and set a $11.00 price objective on the stock in a research report on Tuesday, July 1st. Zacks Research upgraded shares of Black Diamond Therapeutics to a "strong-buy" rating in a research note on Monday, August 11th. Finally, Wall Street Zen lowered shares of Black Diamond Therapeutics from a "buy" rating to a "hold" rating in a research report on Saturday, August 9th. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $12.40.

Black Diamond Therapeutics Stock Down 0.4%

Shares of NASDAQ BDTX traded down $0.01 during midday trading on Wednesday, reaching $2.75. 492,801 shares of the company were exchanged, compared to its average volume of 1,994,022. Black Diamond Therapeutics has a one year low of $1.20 and a one year high of $6.75. The stock has a market cap of $156.59 million, a P/E ratio of 11.96 and a beta of 2.87. The stock's 50-day moving average price is $2.65 and its 200-day moving average price is $2.15.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in BDTX. Hudson Bay Capital Management LP acquired a new stake in Black Diamond Therapeutics during the 2nd quarter valued at approximately $26,000. Tower Research Capital LLC TRC lifted its position in Black Diamond Therapeutics by 217.6% in the second quarter. Tower Research Capital LLC TRC now owns 21,031 shares of the company's stock valued at $52,000 after buying an additional 14,410 shares during the last quarter. Man Group plc acquired a new stake in shares of Black Diamond Therapeutics during the second quarter worth about $103,000. Engineers Gate Manager LP acquired a new stake in shares of Black Diamond Therapeutics during the second quarter worth about $82,000. Finally, Bridgeway Capital Management LLC raised its holdings in Black Diamond Therapeutics by 34.5% in the second quarter. Bridgeway Capital Management LLC now owns 98,300 shares of the company's stock valued at $244,000 after acquiring an additional 25,200 shares in the last quarter. Hedge funds and other institutional investors own 95.47% of the company's stock.

Black Diamond Therapeutics Company Profile

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.